Hopp til innhold
NHI.no
Annonse

Behandling av seboreisk eksem

Innhold i artikkelen

Fjerning av tykke skjell i hodebunnen er viktig for at soppbehandlingen skal ha effekt. Dette gjøres ved at hodebunnen smøres med salisylolje som vaskes ut etter seks timer eller mer. Slik behandling gjentas i noen dager til skjellene er borte. Ved milde former for flass, kan man starte direkte med behandlingen uten skjellfjerning.

Annonse

Sjampo med soppmiddel (for eksempel Fungoral) brukes ved seboreisk eksem i hodebunnen, mens krem med soppdrepende effekt benyttes i ansiktet og andre steder på kroppen. Behandling med mild kortisonkrem med antibakteriell virkning, kan brukes i starten av behandlingen.

Behandlingen er livsvarig. Vanligvis er det en periode med hyppig behandling i to til fire uker før man går over til vedlikeholdsbehandling cirka en gang i uken

Menn som lar skjegget gro, kan redusere plagene ved å trimme skjegget litt slik at sjampoen får virke på huden.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Seboréisk dermatitt . Referanselisten for dette dokumentet vises nedenfor

  1. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician 2015 Feb 1;91(3):185-190.
  2. Sasseville D. Seborrheic dermatitis in adolescents and adults. UpToDate, last updated Mar 26, 2020. www.uptodate.com
  3. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology 2004; 208: 89-93. PubMed
  4. Foley P, Zuo Y, Plunkett A, Merlin K, Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol 2003; 139: 318-22. PubMed
  5. Mastrolonardo M, Diaferio A, Vendemiale G, Lopalco P. Seborrhoeic dermatitis in the elderly: inferences on the possible role of disability and loss of self-sufficiency. Acta Derm Venereol 2004; 84: 285-7. PubMed
  6. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson's disease: a survey of (im)possible links. Med Hypotheses 2003; 60: 907-11. PubMed
  7. Piérard GE. Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment. Dermatology 2003; 206:187-8. PubMed
  8. Schwartz RA. Superficial fungal infections. Lancet 2004; 364: 1173-82. PubMed
  9. Handler MZ. Seborrheic dermatitis. Medscape, last updated Aug 13, 2019. emedicine.medscape.com
  10. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev. 2012;25(1):106–141.
  11. Viodé C, Lejeune O, Turlier V, et al. Cathepsin S, a new pruritus biomarker in clinical dandruff/seborrhoeic dermatitis evaluation. Exp Dermatol. 2014;23(4):274–275.
  12. Schwartz JR, Messenger AG, Tosti A, et al. A comprehensive pathophysiology of dandruff and seborrheic dermatitis - towards a more precise definition of scalp health. Acta Derm Venereol. 2013;93(2):131–137.
  13. Janniger CK, Schwartz RA. Seborrhoeic dermatitis. BMJ Best Practice, last updated Feb 13, 2017. bestpractice.bmj.com
  14. Statens legemiddelverk. Terapianbefaling: Behandling av dermatomykoser. Nytt om legemidler 2005; 28 (2): 28-33.
  15. Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014; 5: CD009446. PMID: 24838779 PubMed
  16. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD008138. DOI: 10.1002/14651858.CD008138.pub3. DOI
  17. Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 2002; 13: 51-60. PubMed
  18. Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology 2003; 206: 233-40. PubMed
  19. Milani M, Antonio Di Molfetta S, Gramazio R, Fiorella C, Frisario C, Fuzio E, et al. Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Curr Med Res Opin 2003; 19: 342-5. PubMed
  20. Reichrath J. Antimycotics: why are they effective in the treatment of seborrheic dermatitis? Dermatology 2004; 208: 174-5. PubMed
  21. Schwartz JR, Rocchetta H, Asawanonda P, Luo F, Thomas JH. Does tachyphylaxis occur in long-term management of scalp seborrheic dermatitis with pyrithione zinc-based treatments? Int J Dermatol. 2009;48(1):79–85.
  22. Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol. 2009. 10(2):103-18.
  23. Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2012;5(1):91–97.
  24. Ooi ET, Tidman MJ. Improving the management of seborrhoeic dermatitis. Practitioner. 2014;258(1768):23–26.
Annonse
Annonse